Immuno-Oncology
Recent updates in CML: treatment strategies, clinical trials, and novel agents
The 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) was held in Houston, TX, from September 28-October 1,…
Date: 11th November 2022
iwNHL Session II: understanding and harnessing the immune microenvironment against lymphoma
The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in…
Date: 9th November 2022
iwAL 2022 Session II: novel treatment strategies in ALL
The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the…
Date: 4th November 2022
The role of the innate immune system in MDS
Myelodysplastic syndromes (MDS) represent a heterogeneous group of diseases which remain a challenge to treat, and immune dysregulation has been…
Date: 2nd November 2022
iwAL 2022 Session I: the standard of care in AML in 2022
The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in…
Date: 28th October 2022
iwNHL 2022 Session I: advances in the treatment of T-cell lymphoma
The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in…
Date: 26th October 2022
Identifying high-risk myeloma and improving treatment strategies in these patients
Multiple myeloma is a heterogeneous disease, and despite recent advances in therapeutic agents, several patients still relapse after therapy and…
Date: 22nd September 2022
Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment
Myeloproliferative neoplasms (MPNs) represent a group of rare and heterogeneous diseases which remain a challenge to treat. Several advances have…
Date: 9th September 2022
The need for more effective first-line therapies in MDS
The treatment and management of myelodysplastic syndromes (MDS) remains a challenge due to the heterogeneity of the disease, and early…
Date: 7th September 2022
Myeloma 2022: day two highlights
There were several fascinating sessions and discussions at the Myeloma 2022 meeting that took place in Scottsdale, AZ. Topics that…
Date: 2nd September 2022
The promise of CAR-T therapy in CLL and challenges in the field
The treatment landscape of chronic lymphocytic leukemia (CLL) has greatly transformed over the years with the introduction of several agents,…
Date: 31st August 2022
T-cell engagers in multiple myeloma: current challenges and future outlooks
Several novel agents have been approved in the field of multiple myeloma and have greatly transformed the treatment landscape of…
Date: 24th August 2022
